08 Nov 2021
PAI Partners (“PAI”), a pre-eminent private equity firm, today announces that it has reached an agreement to sell Atos Medical (“the Company”), a global market leader in supporting patients with a neck stoma, to Coloplast, a Danish multinational company that develops, manufactures, and markets medical devices and services related to ostomy, urology, continence, and wound care, for an enterprise value of c. €2.2 billion.
Founded in Sweden in 1986, Atos Medical was born out of a desire to make life easier for people living with a laryngectomy by providing personalised care and innovative solutions for restoring speaking ability after surgical removal of a patient’s voice box. Today, Atos Medical helps improve the lives of patients following both laryngectomy and tracheostomy procedures.
PAI acquired Atos Medical in 2016. Under its ownership, Atos Medical has developed into a global leader in supporting all patients with a neck stoma. This has been achieved through accelerated expansion in new geographies and through capitalising on the Company’s unique direct-to-consumer set-up in laryngectomy. During PAI’s ownership, the Company has further developed and introduced new customer-centric and clinically superior products. Additionally, the Company has through selective M&A established a second organic growth area in tracheostomy and thus become a true and diversified ENT specialist.
Ragnar Hellenius, Partner at PAI Partners, commented: “We are proud to have been part of Atos Medical’s impressive growth journey under Britt and her team’s inspiring leadership. The Company’s strong organic growth track record and industry leading margins are a testimony to its unique direct-to-consumer set-up as well as its ability to do selective M&A in existing and adjacent segments such as tracheostomy. I feel privileged to have had the opportunity to work alongside Atos Medical’s management team and its employees on their quest to improve the quality of life of neck stoma patients.”
Andreas Kumeth, Partner at PAI Partners, said: “It has been very rewarding to be able to support Atos Medical’s growth in the last few years with the Company more than doubling in size and transforming into a true direct-to-consumer medtech company. We are also proud to have played a role in helping Atos Medical establish further specialities and become a more diversified ENT specialist.”
Closing of the transaction is subject to customary regulatory approvals and is anticipated in Q1 2022.
Headquartered in Sweden, Atos Medical serves customers in ~90 countries and has around 1,150 employees and a direct presence in 30 countries across the world. Atos Medical has a track-record of high single-digit organic growth, solid EBITDA margins and high cash conversion. Approximately 50% of the company’s laryngectomy revenues come from its direct-to-consumer channel.
Linklaters served as Legal Advisor to PAI Partners on the transaction.